These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 33910619)

  • 1. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review.
    Pisaniello HL; Fisher MC; Farquhar H; Vargas-Santos AB; Hill CL; Stamp LK; Gaffo AL
    Arthritis Res Ther; 2021 Apr; 23(1):130. PubMed ID: 33910619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease.
    Bausson J; Keller N; Von Hunolstein JJ; Sacrez M; Michel B; Gourieux B; Fourtage M; Felten R
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38296804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities.
    Stamp LK; Farquhar H; Pisaniello HL; Vargas-Santos AB; Fisher M; Mount DB; Choi HK; Terkeltaub R; Hill CL; Gaffo AL
    Nat Rev Rheumatol; 2021 Oct; 17(10):633-641. PubMed ID: 34331037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges associated with the management of gouty arthritis in patients with chronic kidney disease: a systematic review.
    Curiel RV; Guzman NJ
    Semin Arthritis Rheum; 2012 Oct; 42(2):166-78. PubMed ID: 22560299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of acute gout: a systematic review.
    Khanna PP; Gladue HS; Singh MK; FitzGerald JD; Bae S; Prakash S; Kaldas M; Gogia M; Berrocal V; Townsend W; Terkeltaub R; Khanna D
    Semin Arthritis Rheum; 2014 Aug; 44(1):31-8. PubMed ID: 24650777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review.
    Farquhar H; Vargas-Santos AB; Pisaniello HL; Fisher M; Hill C; Gaffo AL; Stamp LK
    Rheumatol Adv Pract; 2021; 5(1):rkaa073. PubMed ID: 33521512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new perspective on the pharmacoeconomics of colchicine.
    Wertheimer AI; Davis MW; Lauterio TJ
    Curr Med Res Opin; 2011 May; 27(5):931-7. PubMed ID: 21370937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
    Latourte A; Bardin T; Richette P
    Rheumatology (Oxford); 2014 Nov; 53(11):1920-6. PubMed ID: 24758886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors.
    Wechalekar MD; Vinik O; Moi JH; Sivera F; van Echteld IA; van Durme C; Falzon L; Bombardier C; Carmona L; Aletaha D; Landewé RB; van der Heijde DM; Buchbinder R
    J Rheumatol Suppl; 2014 Sep; 92():15-25. PubMed ID: 25180124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive urate-lowering with pegloticase plus methotrexate co-therapy in uncontrolled gout patients with and without chronic kidney disease: A retrospective case series.
    Albert J; Broadwell A; Padnick-Silver L; Marder B; LaMoreaux B
    Medicine (Baltimore); 2024 Mar; 103(10):e37424. PubMed ID: 38457582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing hyperuricemia and gout in chronic kidney disease: a clinical conundrum.
    Premachandra KH; Day RO; Roberts DM
    Curr Opin Nephrol Hypertens; 2021 Mar; 30(2):245-251. PubMed ID: 33399392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GOSPEL 2 - Colchicine for the treatment of gout flares in France - a GOSPEL survey subgroup analysis. Doses used in common practices regardless of renal impairment and age.
    Pascart T; Lancrenon S; Lanz S; Delva C; Guggenbuhl P; Lambert C; Aubert JP; Saraux A; Ea HK; Lioté F
    Joint Bone Spine; 2016 Dec; 83(6):687-693. PubMed ID: 26919801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of anakinra in gout patients with stage 4-5 chronic kidney disease or kidney transplantation: A multicentre, retrospective study.
    Loustau C; Rosine N; Forien M; Ottaviani S; Juge PA; Lioté F; Bardin T; Richette P; Dieudé P; Richez C; Bannwarth B; Schaeverbeke T; Ea HK; Truchetet ME
    Joint Bone Spine; 2018 Dec; 85(6):755-760. PubMed ID: 29654950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Difficult-to-treat gout flares: eligibility for interleukin-1 inhibition in private practice is uncommon according to current EMA approval.
    Pascart T; Norberciak L; Ea HK; Graf S; Guggenbuhl P; Lioté F
    Rheumatology (Oxford); 2019 Dec; 58(12):2181-2187. PubMed ID: 31177284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs for gout.
    Med Lett Drugs Ther; 2019 Mar; 61(1567):33-37. PubMed ID: 30845096
    [No Abstract]   [Full Text] [Related]  

  • 17. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of allopurinol in chronic kidney disease.
    Thurston MM; Phillips BB; Bourg CA
    Ann Pharmacother; 2013 Nov; 47(11):1507-16. PubMed ID: 24259601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
    Kimura K; Hosoya T; Uchida S; Inaba M; Makino H; Maruyama S; Ito S; Yamamoto T; Tomino Y; Ohno I; Shibagaki Y; Iimuro S; Imai N; Kuwabara M; Hayakawa H; Ohtsu H; Ohashi Y;
    Am J Kidney Dis; 2018 Dec; 72(6):798-810. PubMed ID: 30177485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
    Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
    Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.